Search research articles
Contact Us
Filters
Showing results (31-40 of 75) with videos related to
Page
of 8
Sort By:
Oncotarget
|
December 10, 2015
Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma
Rochelle L Tiedemann, Ryan A Hlady, Paul D Hanavan, et al.
Journal of Cancer
|
September 11, 2012
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials
Mitesh J Borad, Kelly K Curtis, Hani M Babiker, et al.
Investigational New Drugs
|
December 18, 2012
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials
Mitesh J Borad, Arundhati D Soman, Martin Benjamin, et al.
Journal of Hematology & Oncology
|
October 21, 2015
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
Raoul Tibes, Aref Al-Kali, Gavin R Oliver, et al.
Leukemia & Lymphoma
|
April 29, 2016
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome
Mathew A Cherian, Raoul Tibes, Feng Gao, et al.
Cancer
|
January 20, 2011
Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials
Raoul Tibes, Barbara F Piper, Jessica A Smith, et al.
Cancer Discovery
|
May 4, 2019
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment
Xufeng Chen, Christina Glytsou, Hua Zhou, et al.
Scientific Reports
|
September 4, 2020
Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin
Andres M Arias Lorza, Harshan Ravi, Rohit C Philip, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 29, 2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
Jeffrey R Infante, Glen J Weiss, Suzanne Jones, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 29, 2021
<sup>68</sup>Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms
Sabrina Kraus, Alexander Dierks, Leo Rasche, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 75) with videos related to
Sort By:
Page
of 8
Oncotarget
|
December 10, 2015
Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma
Rochelle L Tiedemann, Ryan A Hlady, Paul D Hanavan, et al.
Journal of Cancer
|
September 11, 2012
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials
Mitesh J Borad, Kelly K Curtis, Hani M Babiker, et al.
Investigational New Drugs
|
December 18, 2012
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials
Mitesh J Borad, Arundhati D Soman, Martin Benjamin, et al.
Journal of Hematology & Oncology
|
October 21, 2015
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
Raoul Tibes, Aref Al-Kali, Gavin R Oliver, et al.
Leukemia & Lymphoma
|
April 29, 2016
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome
Mathew A Cherian, Raoul Tibes, Feng Gao, et al.
Cancer
|
January 20, 2011
Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials
Raoul Tibes, Barbara F Piper, Jessica A Smith, et al.
Cancer Discovery
|
May 4, 2019
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment
Xufeng Chen, Christina Glytsou, Hua Zhou, et al.
Scientific Reports
|
September 4, 2020
Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin
Andres M Arias Lorza, Harshan Ravi, Rohit C Philip, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 29, 2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
Jeffrey R Infante, Glen J Weiss, Suzanne Jones, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 29, 2021
<sup>68</sup>Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms
Sabrina Kraus, Alexander Dierks, Leo Rasche, et al.
Page
of 8